City of Hope | Strategic Alliance Partners

August 30, 2021

Tanya B. Dorff, MD, discusses biomarkers of response to PARP inhibitors under investigation in prostate cancer.

August 30, 2021

Yung Lyou, MD, PhD, discusses the efficacy of androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

August 25, 2021

Natasha Garg, DO, discusses the emergence of antiandrogen agents in the nonmetastatic castration-resistant prostate cancer treatment paradigm.

August 24, 2021

Leanne Burnham, PhD, discusses the correlation between HER2 positivity and race in patients with prostate cancer.

August 23, 2021

Marwan Fakih, MD, discusses efficacy reported with regorafenib plus nivolumab in patients with mismatch repair–proficient and microsatellite stable metastatic colorectal cancer.

August 23, 2021

Dr. Krie and Dr. Yuan discussed treatment-related adverse effects one should be aware of and prepared to manage, recommended management strategies for these TRAEs, and important points to emphasize to patients before they begin treatment.

August 18, 2021

Alexey V. Danilov, MD, discusses the safety and efficacy achieved with the novel combination comprised of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.

August 09, 2021

City of Hope, a world-renowned cancer research and treatment center, today announced that acclaimed Pacific Shores Medical Group has joined City of Hope.

July 27, 2021

Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.

July 23, 2021

Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.

July 22, 2021

Leanne Burnham, PhD, discusses the need to close the gap in health disparities in prostate cancer.

July 19, 2021

Yung Lyou, MD, PhD, discusses emerging biomarkers in prostate cancer.

July 16, 2021

Yung Lyou, MD, PhD, discusses optimal sequencing with apalutamide in prostate cancer.

July 14, 2021

Leanne Burnham, PhD, discusses health disparities in prostate cancer.

July 14, 2021

Within the hierarchy of clinical trials, phase 3 randomized studies remain the gold standard, though some argue that appropriately designed meta-analysis of multiple studies provides even more definitive and meaningful insight.

July 08, 2021

Dr. Rariy, Ms. Brown, and Ms. Greenman discuss how the COVID-19 pandemic has led to a significant delay in cancer diagnoses, impacted the training of oncologists, and revolutionized telehealth.

June 20, 2021

Tanya Dorff, MD, discusses encouraging data from a study evaluating bright white light in older patients with prostate cancer and updates from the phase ARAMIS trial.

June 19, 2021

City of Hope has entered into a licensing agreement with Imugene Ltd. for the patents covering a combination immunotherapy that enables CD19-directed CAR T-cell therapies to target and eradicate difficult-to-treat solid tumors.

June 16, 2021

Multiple FDA approvals and an increasing number of clinical trials examining molecular target–based therapeutics, including second- or even third-generation drugs against a well-defined target, present an ever-widening array of drugs for routine cancer care based on the discovery of specific molecular targets within the tumor or within the germline.

June 11, 2021

Preeminent oncologist Edward S. Kim, MD, MBA, has been named among the nation’s top cancer leaders by Friends of Cancer Research, a national organization dedicated to advances in science, policy, and regulations that speed lifesaving treatments to patients.